Showing 1 - 10 results of 10 for search 'Jacqueline M. Miller', query time: 0.06s Refine Results
  1. 1
    Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children

    Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young... by Markus Knuf, Yaela Baine, Véronique Bianco, Dominique Boutriau, Jacqueline M. Miller

    Published 2012-07-01
    Get full text
    Article
  2. 2
    Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape

    Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape by Rituparna Das, Randall N. Hyer, Paul Burton, Jacqueline M. Miller, Barbara J. Kuter

    Published 2023-01-01
    Get full text
    Article
  3. 3
    Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment”

    Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment” by Rituparna Das, Randall N. Hyer, Paul Burton, Jacqueline M. Miller, Barbara J. Kuter

    Published 2023-01-01
    Get full text
    Article
  4. 4
    The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults

    The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerate... by Mari Rose Aplasca-De Los Reyes, Efren Dimaano, Noel Macalalad, Ghassan Dbaibo, Véronique Bianco, Yaela Baine, Jacqueline M. Miller

    Published 2012-07-01
    Get full text
    Article
  5. 5
    The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine<subtitle>A randomized, controlled non-inferiority study</subtitle>

    The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tet... by Ghassan Dbaibo, Noel Macalalad, Mari Rose Aplasca-De Los Reyes, Efren Dimaano, Véronique Bianco, Yaela Baine, Jacqueline M. Miller

    Published 2012-07-01
    Get full text
    Article
  6. 6
    Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents

    Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents by Beatriz P. Quiambao, Ashish Bavdekar, Anand Prakash Dubey, Hemant Jain, Devayani Kolhe, Véronique Bianco, Jacqueline M. Miller, Marie Van der Wielen

    Published 2017-03-01
    Get full text
    Article
  7. 7
    Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers<subtitle>A pooled analysis of randomized trials</subtitle>

    Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C... by Kristina A. Bryant, Jodie McVernon, Colin D. Marchant, Terry Nolan, Gary S. Marshall, Peter Richmond, Helen Marshall, Michael Nissen, Stephen B. Lambert, Emmanuel Aris, Narcisa Mesaros, Jacqueline M. Miller

    Published 2012-08-01
    Get full text
    Article
  8. 8
    Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trialResearch in context

    Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trialResearch in context by Amparo L. Figueroa, Kashif Ali, Gary Berman, Honghong Zhou, Weiping Deng, Wenqin Xu, Stephanie Lussier, Bethany Girard, Frank J. Dutko, Karen Slobod, Anne Yeakey, Frances Priddy, Jacqueline M. Miller, Rituparna Das

    Published 2024-08-01
    Get full text
    Article
  9. 9
    Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

    Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19 by Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das

    Published 2023-08-01
    Get full text
    Article
  10. 10
    Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

    Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases by Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout, J. Scott Overcash, Susanne Doblecki-Lewis, Jennifer A. Whitaker, Evan J. Anderson, Kathleen Neuzil, Lawrence Corey, Frances Priddy, Joanne E. Tomassini, Mollie Brown, Bethany Girard, Dina Stolman, Veronica Urdaneta, Xiaowei Wang, Weiping Deng, Honghong Zhou, Avika Dixit, Rituparna Das, Jacqueline M. Miller, the COVE Trial Consortium

    Published 2024-08-01
    Get full text
    Article

Search Tools: